Lundbeck carries on Rexulti study after new analysis
After having received a new interim analysis, Lundbeck and its partner Otsuka have decided to keep going with a phase III study with the drug Rexulti for treating Alzheimer's symptoms.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Danish pharmaceutical company Lundbeck and its partner Japanese pharmaceutical firm Otsuka have long been anticipating the results of their phase III trial with Rexulti, or brexpiprazole, for treating agitation in patients suffering from the dementia disease Alzheimer's.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck drug hope moves closer to moment of truth
For subscribers
